Ruti Aga's Six-Year Ban: A Glucocorticoid, a Forged Prescription and a Marathon Career Ended at 32

There is a sentence in the Athletics Integrity Unit's statement, released on a Thursday, that stops the reading dead: the clinic named on Ruti Aga's medical prescription does not exist. The "doctor" who signed it was a family member with no medical registration. Asked about it, that person said he had used an old prescription pad from a former workplace — and the hospital concerned has disowned the claim outright. Three separate verifications, three denials, and in the middle of them a thirty-two-year-old distance runner whose career rested on a piece of paper. The ban is six years. Two for the substance found in her sample, four for the document she produced. The arithmetic tells a small story of its own: the panel came down twice as hard on the paperwork as on the drug. Aga belongs to the generation that has steadily widened the gap, inside Ethiopian women's marathoning, between "very good" and "selectable." The record is real: second at Berlin 2026 in 2:18:34, victory at the 2026 Tokyo Marathon in 2:20:40, and three World Marathon Majors podium finishes in all. That is the record of a genuinely elite marathoner. It is not a national record. The whole case hangs on that distinction, and I will come back to it. In March she won a half marathon in China. Which race, in what time, against what field, on what splits — none of that is in the AIU statement, and I will not fill it in by guesswork. What is certain: a sample was collected after the win, methylprednisolone was found, and she had been provisionally suspended since 10 September. Thursday's decision converted that provisional suspension into the start date of the ban itself. Six years means she returns at roughly thirty-eight, assuming she returns. Now to the technical error that travelled around the world with this story and quietly rewrote its moral. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List. It is not an anabolic steroid, which is class S1. Several reports called it a "prohibited steroid," which is pharmacologically wrong. And the error is not merely verbal. S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection administered out of competition is entirely legal. Which means this was never a steroid case. It was a case about route and timing. Here the road-racing testing window matters, because the lesson I learned in an empty Patiala stadium runs in reverse out on the road. In a silent stadium you hear the breathing; on the road you inherit a clock. A road race's in-competition window opens at 23:59 the day before the race. An injection given three days earlier is caught if residue remains. But that same fact contained Aga's defence: documented treatment, the route on record, the timing accounted for, or a therapeutic use exemption. Any one of those roads led out. She took a third road and had a prescription manufactured. That is the moment the defence that could actually have worked died. The six-year arithmetic makes it explicit. Two years for the presence violation, meaning the panel treated it as a specified substance with no proven intent and no aggravating conduct. Four years for tampering, the standard Code sanction. Two plus four. What speaks loudest in that sum is the refusal of the no-significant-fault mitigation. With genuine medical records the presence charge could have collapsed to a reprimand or a much shorter period, and the tampering charge would never have existed. With a TUE-consistent plan and correct washout timing, there would have been no case at all. The real indictment here is not chemical but structural. The "doctor" was an unregistered relative. The clinic did not exist. The old prescription pad was disowned by the hospital it supposedly came from. Three independent verification failures. That is not a filing error; it is the biography of an athlete operating without a credentialed team physician. Chronic knee pathology is not an exception in marathon running, it is the ordinary price of high volume, and the medical scaffolding is exactly what that price demands. When the scaffolding is missing, people start arranging their own treatment. What survives deserves care too. The violation is anchored to the March race, and the statement does not say whether earlier results are annulled. In principle the 2026 Tokyo title and the Major podiums stand. The March result and its prize money are almost certainly voided, since AIU practice disqualifies the competition at which the sample was collected, though the statement does not spell out the scope. Here is the inverted reading that did not travel with the story. The ban is six years; the drug accounts for two. Four belong to the paper. The enforcement frontier has shifted from detection to document verification. Aga's case is not an outlier but a member of a recognisable family in East African road running, where the first violation is a substance and the second, heavier one is the explanation built around it. To see the longitude of that shift you have to look at the economy underneath: between Majors, the Chinese label-race circuit is the most accessible and lucrative income tier for East African marathoners. It is also now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. And one uncomfortable fact: glucocorticoids have no proven endurance benefit. An injection that muffles knee pain is not a performance enhancer, it is a tool for tolerating pain. Yet six years were handed down, and that number will be cited two ways — as evidence of AIU rigour, and as evidence of disproportionate enforcement against African road runners. Both sides are half right, because the sentence was passed on the lie, not the drug, and that nuance will get lost. What to watch is clear. Whether the March result and prize money are formally annulled or left inside the statement's ambiguity. Whether a CAS appeal is filed inside the roughly twenty-one-day window, though appealing a document-based finding is a paper war. And above all whether the investigation travels past the one family member, because the agent or management that accepted that prescription is named nowhere. No statement has come from the Ethiopian federation either, and that Patiala night in 2026 reminds me that silence has a chorus — it is just that nobody is recording it. The image that stays is a Tokyo morning in 2026, arms raised at the finish, and years later a file whose heaviest exhibit is a prescription written by a doctor who is registered nowhere, from a clinic that was never built. The most expensive things in this sport have always happened off-camera.